Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investigated whether dual Ang-2/VEGF inhibition could overcome resistance to anti-VEGF treatment. We treated mice bearing orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xenografts with antibodies inhibiting VEGF (B20), or Ang-2/VEGF (CrossMab, A2V). We examined the effects of treatment on the tumor vasculature, immune cell populations, tumor growth, and survival in both the Gl261 and MGG8 tumor models. We found that in the Gl261 model, which displays a highly abnormal tumor vasculature, A2V decreased vessel density, delayed tumor growth, and prolonged survival compared with B20. In the MGG8 model, which displays a low degree of vessel abnormality, A2V induced no significant changes in the tumor vasculature but still prolonged survival. In both the Gl261 and MGG8 models A2V reprogrammed protumor M2 macrophages toward the antitumor M1 phenotype. Our findings indicate that A2V may prolong survival in mice with GBM by reprogramming the tumor immune microenvironment and delaying tumor growth.
anti-angiogenic therapy | tumor microenvironment | anti-tumor immunity | macrophage polarization | microglia reprogramming G lioblastoma (GBM) is the most common primary malignant brain tumor in adults. Even after maximal safe resection and chemoradiation, most patients survive little more than 1 y (1, 2). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), was conditionally approved in 2009 in the United States for treatment of recurrent GBM (rGBM) (2) (3) (4) (5) . Adding bevacizumab to the standard regimen of radiotherapy and alkylating chemotherapy with temozolomide confers an increase in progression-free survival (PFS) but does not improve overall survival in newly diagnosed GBM (nGBM) patients (6, 7) . Similarly, cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, fails to improve overall survival in patients with rGBM (8) . Most recently a European Organization for the Research and Treatment of Cancer randomized phase III trial (EORTC 26101) showed that bevacizumab plus lomustine does not improve survival in patients with progressive GBM, although it prolongs progression-free survival (9) . We previously have shown that angiopoietin-2 (Ang-2) is a resistance pathway to anti-VEGF therapy in a preclinical model of GBM (10) . Ang-2 competes with angiopoietin-1 (Ang-1) in binding to the TEK receptor tyrosine kinase (Tie-2) receptor (11, 12) . In physiological settings, Ang-1 activates Tie-2 and stabilizes blood vessels, whereas Ang-2 inhibits
Significance
Improving survival of patients with glioblastoma (GBM) using antiangiogenic therapy remains a challenge. In this study we show that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels. The antitumor immunomodulatory potential of this dual blockade supports clinical testing of this approach for GBM with other immunotherapeutic approaches such as checkpoint blockers.
Tie-2 signaling, destabilizes blood vessels, and facilitates VEGFinduced angiogenesis in a context-dependent manner (13) . In tumors, however, Ang-2 may act as a partial Tie-2 agonist, conferring therapy resistance by protecting endothelial cells (EC) from therapeutic VEGF withdrawal (14) . The tumor growth-supportive role of Ang-2 in GBMs is not confined to the vascular compartment. Ang-2 also has been shown to mediate the homing of Tie-2 + macrophages to human GBMs (15, 16) . In the tumor microenvironment, the macrophage population then is reprogrammed to a protumor (17) (18) (19) , proangiogenic phenotype (20) (21) (22) in an Ang-2-dependent manner (22) . Tumor-associated macrophages (TAMs) have a broad phenotypic spectrum, and their polarization can change in response to their microenvironment. The two extremes of the phenotypic spectrum of TAMs are defined as the alternatively activated protumor (M2) versus classically activated antitumor (M1) states (23) (24) (25) . We previously have shown that the degree of TAM infiltration in GBM patients treated with anti-VEGF therapy is inversely correlated with survival (26) . These data point to the role of TAMs as potential mediators of resistance to anti-VEGF therapy in GBM. Here we used a dual Ang-2/VEGF-inhibiting antibody (A2V) in orthotopic syngeneic (Gl261 graft) and patient-derived cell line (MGG8 xenograft) models of GBM. We show that A2V treatment can reprogram TAMs to the antitumor M1 state. Moreover, we further dissect the reprogramming effects in the overall TAM population and show that both recruited macrophages and resident microglia can be therapeutically altered by dual Ang-2/VEGF inhibition. Combined anti-Ang-2/VEGF therapy was shown to delay tumor growth and prolong survival in a number of extracranial tumor models (27) (28) (29) (30) . Although anti-Ang-2/VEGF therapy is being tested in GBM patients (NCT01609790, NCT01248949, NCT01290263) and in other solid malignancies (Table S1 ). The bispecific antibody A2V has been shown to be safe in a first-in-human study (NCT01688206) in patients with locally advanced or metastatic solid tumors (31) . Here we show that the murinized Ang-2/VEGFneutralizing antibody A2V (CrossMab) is effective in two different GBM models and delays tumor growth through vascular and/or immunomodulatory effects.
Results
Ang-2/VEGF Inhibition Delays Tumor Growth and Prolongs Survival.
We first validated Ang-2 as a potential target in GBM patients by analyzing publicly available data portals, i.e., The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (32) (33) (34) . We found that Ang-2 is expressed in newly diagnosed GBM [nGBM] and rGBM (Fig. S1A ) across molecular subtypes (Fig.  S1B ), significantly correlates with VEGF expression (Fig. S1E) , and is predominantly expressed in GBM blood vessels in patients ( Fig. S1 C and D) . Next we investigated the effects of blocking Ang-2 and VEGF alone or in combination with Ang-2 in an orthotopic syngeneic murine GBM model (Gl261 in C57BL/6 mice). The Gl261 model recapitulates abnormal GBM tumor vessels and the presence of intratumoral foci of necrosis and displays a moderate degree of invasion into the surrounding brain. We treated Gl261-bearing animals with IgG control or with antibodies inhibiting Ang-2 (LC06), VEGF (B20), or Ang-2/VEGF (A2V) and found that all experimental therapies increased survival compared with IgG control (Fig. 1A) . In addition, we found that A2V treatment significantly extended median survival compared with either LC06 or B20 alone (Fig. 1A) . Next we tested if the effects we observed in the Gl261 model were conserved in the MGG8 model. The MGG8 model is characterized by extensive single-cell invasion but a tumor vasculature that is less abnormal than seen with Gl261. In the MGG8 model, both LC06 and B20 failed to confer a survival benefit compared with IgG, but A2V prolonged survival compared with all treatment groups (Fig. 1B) . To assess the antiangiogenic potential of LC06, B20, and A2V, we next measured the effects of these antibodies on primary ECs (human umbilical vein ECs, HUVECs) in a microfluidic chamber assay (Fig. S2) . We found that the combination of recombinant VEGF (rVEGF) plus recombinant Ang-2 (rAng-2) strongly induced sprouting in HUVECs. HUVEC sprouting induced by exogenous rVEGF alone was significantly inhibited by B20 but not by LC06 (Fig. S2 A-F). HUVEC sprouting induced by rVEGF plus rAng-2 ( Fig. S2J ) also was significantly inhibited by B20 ( Fig. S2 K and L) but was not decreased by LC06 and was completely abrogated by A2V (Fig. S2M) . Importantly, exogenous rAng2-induced EC sprouting was completely abolished not only by LC06 but also by B20 in the absence of exogenous rVEGF ( Fig. S2 G-I ). The angiogenic effect of Ang-2 appears to be dependent on VEGF signaling, which may contribute to the contextdependent functions of Ang-2. Based on these data and our observation that LC06 did not confer a survival benefit in the MGG8 model, we determined that Ang-2 blockade requires additional VEGF inhibition to inhibit angiogenesis effectively. Therefore we focused all further analyses on B20 and A2V compared with control.
In additional animal experiments we harvested GBM specimens for histological analyses in a time-matched fashion at a time point when viable tumor burden-as a surrogate of viable tumor burden ( Fig. S3 A and D)-was significantly different from control: Gl261 tumors were harvested on day 5, and MGG8 tumors at day 10 after treatment initiation. To determine if antiangiogenic treatments with B20 and A2V decrease tumor burden, we monitored blood Gaussia luciferase (Gluc) activity (35-37) daily in Gl261-GFPGluc-bearing mice treated with IgG, B20, or A2V. Reduced blood Gluc activity in A2V-treated animals suggested lower tumor burden as compared with IgG or B20 treatment (Fig. S3B) . Moreover, using the 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay, we found that Gl261 tumors of A2V-treated animals exhibited reduced proliferation compared with IgG control or B20 therapy (Fig. S3C) .
In the MGG8 model, levels of blood Gluc activity were lower in B20-and A2V-treated animals than in animals treated with IgG, suggesting therapy-induced reduction of viable tumor burden (Fig. S3E) . Comparisons in the kinetics of tumor burden between B20-and A2V-treated MGG8-bearing animals failed to reach significance (Gluc assay). However, we measured significantly reduced tumor proliferation (EdU assay) in A2V-compared with B20-treated tumors (Fig. S3F ). We detected no significant difference in apoptosis between the treatment groups in either Gl261 or MGG8 tumors ( Fig. S4 A and B) . Further in vitro experiments showed that neither B20 nor A2V had a direct effect on GBM cell viability in these models ( .97, ***P = < 0.001, n = 10], LC06 (HR 2.99, 95% CI 1.6-13.49, **P = 0.0098, n = 9), and B20 (HR 2.35, 95% CI, 1.31-9.12, *P = 0.03, n = 10) treatment. LC06 prolonged survival compared with IgG treatment (HR 2.32, 95% CI 1.31-8.98, *P = 0.03, n = 9), and B20 increased survival compared with IgG treatment (HR 2.68, 95% CI 2.03-14.58, **P = 0.005, n = 10). (B) In the MGG8 model treatment with LC06 (n = 9) or B20 (n = 9) did not prolong survival compared with IgG treatment (n = 10). Therapy with B20 significantly prolonged survival compared with LC06 therapy (HR 2.48, 95% CI 1.47-11.31, *P = 0.02, n = 9). Therapy with A2V (n = 10) prolonged survival compared with IgG (HR 3.83, 95% CI 4.07-35.39, ***P < 0.001), LC06 (HR 4.14, 95% CI 4.76-49.81, ****P = < 0.001, n = 9), and B20 (HR 2.28, 95% CI 1.51-11.13, *P = 0.03, n = 9) therapy. Time represents days post treatment initiation. Animals were treated once weekly i.p. with 10 mg/kg of IgG control, B20, LC06, or A2V.
mice bearing Gl261 and MGG8 tumors by reducing in vivo tumor burden.
A2V Enhances Vessel Pruning as Compared with VEGF Inhibition Alone
in the Gl261 Model. To determine if vessel-modulating effects are responsible for the prolonged survival and reduced tumor burden in the A2V group, we studied the effects of A2V on Gl261 tumor vessels (Fig. 2 A-G) . The vasculature of Gl261 tumors is characterized by lower microvessel density (MVD) (Fig. 2H ) and larger vessel diameters (Fig. 2I ) than seen in the vasculature of the normal brain ( Fig. 2 H-K) . Using immunohistochemistry in Gl261 tumor tissues, we found that A2V-treated tumors displayed a lower MVD than IgG-treated tumors at day 5 after treatment initiation ( Fig. 2A) . Perivascular cells stabilize tumor vessels and can confer resistance to antiangiogenic treatment (38, 39) . We found that the MVD of immature vessels with low pericyte coverage was significantly decreased (Fig. 2B) . In contrast, the MVD of mature vessels with high pericyte coverage was similar across treatment groups (Fig. 2C) . Interestingly, A2V treatment in the Gl261 model further increased pericyte coverage of the remaining pericyte-high vessels, as compared with IgG and B20 treatments (Fig. 2 D-G) . Collectively, our experiments show that in Gl261 tumors more potent antiangiogenic effects on immature pericytelow vessels are seen with A2V treatment than with B20 treatment.
A2V Reduces Tumor Burden in the MGG8 Model Without Vessel
Pruning. Next, we tested if the vascular effects observed in the Gl261 model (Fig. 2 A-G) could also be observed in the MGG8 model (Fig. 3 A-H) . The MGG8 vasculature showed a lower degree of abnormality, with vessel architecture resembling the normal mouse brain (Fig. 3 H-K) . MGG8 tumors have a higher MVD than the Gl261 model (Fig. 3H) , and vessels are homogeneously distributed, less tortuous, and smaller in diameter (Fig. 3  I-K) . Immunohistochemical analyses showed that, in contrast to the Gl261 model, A2V treatment induced no significant changes in MVD or pericyte coverage compared with B20-or IgG-treated MGG8 tumors (Fig. 3 A-D) . These results indicate that the reduction of tumor burden after A2V treatment in the MGG8 model is mediated by effects other than vessel modulation.
A2V Treatment Promotes an Antitumor Macrophage Phenotype.
Glioma-associated immune cell populations have the potential to create and maintain tumor progression and immunosuppression.
To study the impact of antiangiogenic therapy on the tumor immune microenvironment, we analyzed cellular compartments of Gl261 tumors. First, we measured the presence and activation status of CD4 + and CD8 + T cells of Gl261 tumors treated for 10 d with IgG, B20, or A2V (Fig. S5) . Next, we analyzed the presence and quantity of CD4
+ and CD8 + T cells among lymphocytes and assessed their state of activation. In further analyses we measured the presence of the T-regulatory suppressive phenotype (Fig. S5) and the activation and proliferation state of CD4 + and CD8 + cells (Fig. S6 ). Our data indicate that treatment with B20 or A2V did not induce changes in the number, proliferation, or activation state in T-cell subsets within tumors. In further analyses, we measured the number and phenotype of TAMs. Our data indicate no significant changes in the presence of TAMs (as a percentage of total CD45
+ cells) among the treatment groups (Fig. 4) . However, the percentage of M1-polarized antitumor TAMs (defined as CD206 of total macrophages) was significantly higher in A2V-treated tumors than in controls (Fig. 4 D and G-I) . Moreover, the percentage of protumor M2 TAMs (defined as CD206 high /CD11c low ) was decreased by both B20 and A2V treatment (Fig. 4 E and G-I) . The resulting ratio of M1/M2 TAMs was skewed toward the antitumor M1 phenotype (Fig. 4F) . Within the total TAM population we distinguished between TAMs recruited from the blood circulation versus resident microglia populations. Our data indicate that changes in the overall TAM population were mediated chiefly by a phenotypic shift in recruited TAMs (Figs. S7 and S8 ). In agreement with these data, we found gene expression changes in TAMs suggestive of enhanced M1 (Cxcl9, Il6) and reduced M2 (CD206) polarization (Fig. S9) . We observed no changes in the percentage of CD45
+ myeloid-derived suppressor cells (MDSCs) after treatment with B20 or A2V in the tumors (Fig. S10 A-C) . Consistent with the data from the Gl261 model, flow cytometric analyses of MGG8 tumors after 10 d of treatment showed that therapy with IgG, B20, or A2V did not change the percentage of TAMs (Fig. 5) . Moreover, A2V therapy and, to a lesser extent, B20 therapy also increased the percentage of M1 TAMs in MGG8 tumors as compared with IgG treatment (Fig. 5 D and G-I) . Importantly, treatment with A2V reduced the percentage of protumor M2 macrophages as compared with IgG treatment. Treatment with B20 induced a similar reduction in M2 TAMs compared with IgG treatment (Fig. 5 E and G-I) . The M1/M2 TAM ratio was significantly increased by A2V therapy (Fig. 5F ). We observed significant reprogramming effects toward the M1 phenotype in both the recruited TAMs and the microglia after treatment with B20 and A2V (Figs. S11 and S12). As seen in the Gl261 model, MDSC infiltration was not affected by treatment with either B20 or A2V (Fig. S10 C-E) .
Discussion
To date, targeting the VEGF pathway has failed to prolong overall survival in GBM patients (2, 6, 7, 9) . We and others have shown previously that the elevation of Ang-2 levels may compromise the benefits of anti-VEGF therapy in preclinical GBM models (10, 14) . Here, we tested whether dual inhibition of VEGF (with B20) and Ang-2 (with LC06) with a bispecific antibody (A2V) could improve therapy outcome over antiangiogenic monotherapy. Our study shows that A2V inhibits tumor growth and prolongs the survival of mice bearing syngeneic or human xenograft tumors as compared with anti-Ang-2 or VEGF therapy alone. These results are consistent with the effects of anti-Ang-2/VEGF therapy in extracranial tumor models (14, (27) (28) (29) (30) 40) . We further demonstrate in the Gl261 model that A2V prunes pericyte-low immature vessels, reducing microvascular density. In addition, A2V may reduce microvessel density by inhibiting EC sprouting. HUVEC sprouting was induced by rVEGF and by rAng-2, and sprouting was abrogated by the neutralization of both factors with A2V. Importantly, sprouting induced by rAng-2 plus rVEGF was inhibited by B20 and was completely abrogated by A2V but not by LC06 monotherapy. Surprisingly, B20-mediated neutralization of VEGF abrogated the sprouting induced by VEGF as well as that induced by Ang-2. The efficacy of B20 in reducing Ang-2-induced sprouting is in line with the codependent function of Ang-2 and VEGF in this angiogenic process (11, 14) .
Although A2V delays tumor growth, it fails to achieve longterm inhibition of Gl261 tumor growth. Our data suggest that pericyte-high (mature) vessels are resistant to B20 and A2V therapy and therefore may support sustained tumor growth (39, 41, 42) . These results are in line with the effects of VEGF pathway inhibition described in preclinical tumors in our companion paper (43) and by others (42, 44) , as well as our observations in breast cancer patients (45) that bevacizumab pruned vessels and normalized the remaining vasculature.
Many of the effects of dual anti-Ang-2/VEGF therapyincluding the delay in tumor growth-were seen in a human GBM xenograft model (MGG8). In the MGG8 model, however, the benefits were more limited and occurred in the absence of any apparent antivascular effects. The differential vascular response to A2V in the Gl261 and the MGG8 models may be related to the structural differences in their vasculature; although Gl261 vessels are highly abnormal, MGG8 vessels are homogeneously distributed, and their architecture more closely resembles that of the normal mouse brain. Previously, it has been proposed that different blood vessel phenotypes exhibit differential susceptibility to anti-VEGF therapy (12, 46) . Our results suggest that the tumor vessel phenotype also may be an important determinant of vascular response to dual anti-Ang-2/VEGF blockade, with immature vessels being most susceptible to therapy. Importantly, vascular phenotypes could be studied by imaging in GBM patients. For example, we demonstrated in clinical trials that vessel architectural imaging (VAI) could characterize the vascular phenotype and identify GBM patients who respond to anti-VEGF pathway inhibition (47, 48) . Thus, VAI potentially may identify patients likely to benefit from the vascular component of dual anti-Ang-2/VEGF therapy.
In histological studies we detected no effects of either B20 or A2V on the rate of cancer cell apoptosis in either Gl261 or MGG8 tumors. This finding is confirmed further by the viability assays we conducted, showing no direct cytotoxic or cytostatic effects of A2V, and by data showing that the inhibition of the Tie2 pathway alone does not have cytotoxic effects in multiple tumor models (49) . Indeed, neither Gl261 nor MGG8 express Tie2 (Fig.  S4) . However, A2V therapy reduced tumor cell proliferation as compared with B20 therapy both in Gl261 and MGG8 tumors, despite the differences in antivascular effects in these tumors.
Resident and infiltrating immune cells comprise a major component of the tumor microenvironment. Depending on the state of the disease or treatment, the immune compartment can either promote or inhibit tumor growth (50, 51) . Among immune cells, the ability of T cells to eradicate tumor cells has been studied extensively (50) . Treating tumors with mono (B20) or dual antiangiogenic therapy (A2V) did not alter the presence of T cells or the specific functional T-cell phenotype (effector versus regulatory) in the tumors (Fig. S5) . These CD4 + and CD8 + T cells were highly proliferative and were in an activated state regardless of the treatment (Fig. S6) , suggesting that these T cells did not specifically differ in their exhaustion/anergy. It also should be noted that natural killer (NK) cells can impart antitumor functions independent of CD8 + T-cell activation, although a previous report documented that NK cells have a lesser antitumor effect than CD8 + T cells in Gl261 tumors (52) . In addition, we studied TAMs as an abundant immune cell component in GBMs that may home to tumors in an Ang-2-dependent manner (15, 16) and promote tumor growth (18, 53, 54) . Our finding that A2V treatment reprograms TAMs along the M1-M2 continuum toward the M1 phenotype in both Gl261 and MGG8 tumors may explain the survival benefit observed in these preclinical models, including the benefits seen with anti-Ang-2 monotherapy. This finding could have implications for the sequencing of potential combinatorial regimens of antiangiogenic agents with immunotherapy, because M1-polarized macrophages and microglia may hamper the efficacy of oncolytic herpes simplex virus-1 GBM therapy (55) . The role of TAMs in GBM progression is highlighted further by the data presented in our companion paper (43) , in which we demonstrate that TAM depletion with anti-CSF-1 antibody compromises the survival benefit of dual antiangiogenic therapy (Table S2) .
Interestingly, reprogramming of the overall TAM population by A2V was largely attributable to recruited TAMs in Gl261 tumors and not to resident microglia. In contrast, we observed reprogramming of resident microglia-derived TAMs in the MGG8 tumors in SCID mice. The reprogramming may be caused by the large presence of microglia populations in SCID mice bearing MGG8 tumors as compared with C57BL mice bearing Gl261 tumors, in line with published data (56) .
In summary, we show that dual Ang-2/VEGF blockade can increase the survival of mice bearing GBM over anti-VEGF therapy alone. This increased survival may be the result of the reprogramming of GBM-associated TAMs from the protumor M2 phenotype toward the antitumor M1 phenotype, as observed in both syngeneic murine tumors and human tumor xenografts. In GBMs with a high degree of vascular abnormality, this dual blockade approach also caused antivascular effects. These data support the development of anti-Ang-2/VEGF blockade for GBM alone or with immunotherapy (49, 57) .
Materials and Methods
C57BL/6 mouse-syngeneic Gl261 cells (Frederick National Laboratory, National Cancer Institute) and human MGG8 GBM cells (58) were stereotactically implanted in the brains of male C57BL/6 mice and SCID mice, respectively. Tumor size was assessed by measuring circulating Gluc (35) activity in the blood. Treatment was initiated at a predefined Gluc blood activity ( Fig. S3 A and D) , and tumor burden was measured over time by serial blood Gluc measurements. Animals were treated with IgG, LC06 (Ang-2 antibody), B20 (VEGF antibody), or A2V (bispecific Ang-2/VEGF, CrossMab;) once weekly i.p. at 10 mg/kg. Brains were harvested at the described time points after injection of EdU and were paraffin embedded for histological analyses. The tissues were assessed for cell proliferation (EdU), microvessel density (CD31), and pericyte coverage (desmin). All animal procedures followed Public Health Service Policy on Humane Care of Laboratory Animals guidelines and were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. The use of patient samples was approved by the internal review board of Massachusetts General Hospital. Experimental procedures and methods are described in detail in SI Materials and Methods.
